Clinical and immunologic response without decrease in virus load in patients with AIDS after 24 months of highly active antiretroviral therapy

Clinical Infectious Diseases

Volumn 29, Issue 6, 1999, Pages 1423-1430

  Mezzaroma, Ivano ^a   Carlesimo, Maurizio ^a   Pinter, Elena ^a   Muratori, Donatella Santini ^b   Di Sora, Fiorella ^a   Chiarotti, Flavia ^b   Cunsolo, Maria Giovanna ^a   Sacco, Giovanna ^b   Aiuti, Fernando ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b ISTITUTO SUPERIORE DI SANITÀ   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; DIDANOSINE; INDINAVIR; LAMIVUDINE; RITONAVIR; STAVUDINE; ZALCITABINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; RELAPSE; SURVIVAL; T LYMPHOCYTE; VIRUS LOAD;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTI-HIV AGENTS; CD4-POSITIVE T-LYMPHOCYTES; CLINICAL TRIALS; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; LOGISTIC MODELS; LYMPHOCYTE COUNT; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE INHIBITORS; RNA, VIRAL; SURVIVAL ANALYSIS; T-LYMPHOCYTES; TIME FACTORS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 0033390334     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/313520     Document Type: Article

References (33)

1. 1. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med 1997; 337:725-33.
2. 2. Gulick RM, Mellors JW, Havlir D, et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 1997; 337:734-9.
3. + T cell homeostasis and function in advanced HIV disease. Science 1997; 277:112-6.
4. + T-cell repertoire that are not immediately restored by antiviral or immune-based therapies. Nat Med 1997; 3:533-40.
5. 5. Cameron DW, Heat-Chiozzi M, Danner S, et al. Randomized placebo controlled trial of ritonavir in advanced HIV-1 disease. Lancet 1998; 351: 543-9.
6. 6. Mouton Y, Alfandari S, Valette M, et al. Impact of protease inhibitors on AIDS-defining events and hospitalizations in 10 French AIDS reference centers. AIDS 1997; 11:F101-5.
7. 7. Chiasson MA. Declining AIDS mortality in New York City. Bull N Y Acad Med 1997; 74:151-2.
8. 8. Palella FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998; 338:853-60.
9. 9. Ledergerber B, Egger M, Opravil M, et al. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Lancet 1999; 353:863-8.
10. + T cell subset in response to highly active antiretroviral therapy in HIV type 1 infected patients with prior protease inhibitor experience. AIDS Res Hum Retroviruses 1998; 14:561-9.
11. 11. Carr A, Samaras K, Burthon S, et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia, and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998; 12:F51-8.
12. 12. Carr A, Samaras K, Chisholm DJ, Cooper DA. Pathogenesis of HIV-1 protease inhibitor associated peripheral lipodystrophy, hyperlipidaemia and insulin resistance. Lancet 1998; 351:1881-3.
13. 13. Emery S, Lane HC. Immune reconstitution in HIV infection. Curr Opin Immunol 1997; 9:568-72.
14. 14. Li TS, Tubiana R, Katlama C, Calvez V, Ait Mohand H, Autran B. Long-lasting recovery in CD4 T-cell function and viral-load reduction after highly active antiretroviral therapy in advanced HIV-1 disease. Lancet 1998; 351:1682-1686.
15. 15. Kaufmann D, Pantaleo G, Sudre P, Telenti A. CD4-cell count in HIV-1-infected individuals remaining viraemic with highly active antiretroviral therapy (HAART). Lancet 1998; 351:723-4.
16. 16. Centers for Disease Control and Prevention. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Morb Mortal Wkly Rep 1993; 41:1-19.
17. 17. Schockmel GA, Yerly S, Perrin L. Detection of low HIV-1 RNA levels in plasma. J Acquir Immune Defic Syndr Hum Retrovirol 1997; 14:179-83.
18. 18. Sherer R. Adherence and antiretroviral therapy in injection drug users. JAMA 1998; 280:567-8.
19. 19. Fatkenheuer G, Rockstroh J, Salzberger B. Virological treatment failure of protease inhibitor therapy in an unselected cohort of HIV-infected patients. AIDS 1998; 12:1402-3.
20. 20. Perrin L, Telenti A. HIV treatment failure: testing for HIV resistance in clinical practice. Science 1998; 280:1871-3.
21. 21. D'Arminio Monforte A, Testa L, Adorni F, et al. Clinical outcome and predictive factors of failure of highly active antiretroviral therapy in antiretroviral-experienced patients in advanced stages of HIV-1 infection. AIDS 1998; 12:1631-7.
22. 22. Jacobson MA, Zegans M, Pavan RR, et al. Cytomegalovirus retinitis after initiation of highly active antiretroviral therapy. Lancet 1997; 349: 1443-5.
23. 23. Mallolas J, Arrizabalaga J, Loncà M, et al. Cytomegalovirus disease in HIV-1 infected patients treated with protease inhibitors. AIDS 1997; 11: 1785-7.
24. 24. Lebbe C, Blum L, Pellet C, et al. Clinical and biological impact of antiretroviral therapy with protease inhibitors on HIV-related Kaposi's sarcoma. AIDS 1998; 7:F45-9.
25. 25. Furrer H, Egger M, Opravil M, et al. Discontinuation of primary prophylaxis against Pneumocystis carinii pneumonia in HIV-1-infected adults treated with combination antiretroviral therapy. N Engl J Med 1999; 340:1301-6.
26. 26. André P, Groettrup M, Klenerman P, et al. An inhibitor of HIV-1 protease modulates proteasome activity, antigen presentation, and T cell responses. Proc Natl Acad Sci USA 1998; 95:13120-4.
27. 27. Faye A, Race E, Obry V, et al. Viral fitness in patients with discordant CD4 and plasma HIV RNA evolution following protease inhibitor failure [abstract 331]. In: Program and abstracts of the 6th Conference on Retroviruses and Opportunistic Infections (Chicago, IL). Alexandria, VA: Foundation for Retroviruses and Human Health, 1999.
28. 28. Mellors JW, Kingsley LA, Rinaldo CR, et al. Quantitation of HIV-1 RNA in plasma predicts outcome after seroconversion. Ann Intern Med 1995; 122:573-9.
29. + lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med 1997; 126:946-54.
30. 30. Shaw AJ, McLean KA, Evans BA. Disorders of fat distribution in HIV infection. Int J STD AIDS 1998; 9:595-9.
31. 31. Carpenter CJ, Fischl MA, Hammer SM, et al. Antiretroviral therapy for HIV infection in 1998: updated recommendations of the International AIDS Society - USA Panel. JAMA 1998; 280:78-86.
32. 32. Centers for Disease Control and Prevention. Report of the NIH Panel to Define Principles of Therapy of HIV Infection. MMWR Morb Mortal Wkly Rep 1998; 47(RR-5).
33. 33. Vella S, Mildvan D. Clinical treatment (an overview). AIDS 1998; 12:S147-8.